Streetbeat News

NGENF

NervGen Pharma Corp

Industry

Medicinal and Botanical Manufacturing

Open

1.90

Mkt cap

134M

Volume

4.6K

High

1.90

P/E Ratio

-7.30

52-wk high

2.42

Low

1.90

Div yield

N/A

52-wk low

1.20

NervGen Pharma Corp. has granted 545,000 incentive stock options to its employees and consultants, including 100,000 to officers and 15,000 to investor relations consultants, at an exercise price of $2.74 per share.

Portfolio Pulse from

March 14, 2025 | 11:45 pm

NervGen Pharma Corp. will present at the Virtual Life Science Investor Forum on March 13, 2025. The presentation will be led by CEO Mike Kelly and is hosted by OTC Markets Group and VirtualInvestorConferences.com.

Portfolio Pulse from

March 05, 2025 | 1:45 pm

NervGen Pharma Corp. has granted 627,200 incentive stock options to its employees, including 505,200 to its Officers, at $2.97 per share, vesting over two years.

Portfolio Pulse from

February 18, 2025 | 9:45 pm

NervGen has completed enrollment for its phase 2 trial in spinal cord injury, with results expected in Q2 2024. Positive results could significantly impact the perception of NervGen's stock value, as the company may have a breakthrough in nervous system regeneration.

Portfolio Pulse from

January 10, 2025 | 10:00 am

NervGen's NVG-291 shows promising preclinical results for spinal cord injury treatment, with significant improvements in motor function and nerve regeneration. The company is conducting a Phase 1b/2a trial, with data expected by mid-2025. FDA Fast Track Designation enhances its chances for Accelerated Approval.

Portfolio Pulse from

December 25, 2024 | 6:45 am

NervGen Pharma Corp. has announced an 'at-the-market' equity program allowing the company to issue and sell common shares through Stifel Nicolaus Canada Inc. This program provides NervGen with flexibility in raising capital as needed.

Portfolio Pulse from

December 20, 2024 | 12:45 pm

NervGen Pharma Corp. reported its Q3 2024 financial results, highlighting progress in its clinical trials for NVG-291 and preclinical studies for NVG-300. The company is nearing completion of participant enrollment for its Phase 1b/2a trial in spinal cord injury.

Portfolio Pulse from

November 14, 2024 | 1:45 pm

NervGen Pharma Corp., a clinical-stage biotech company, will present at the Stifel 2024 Healthcare Conference. The company's President & CEO, Mike Kelly, will participate in a fireside chat on November 18, 2024.

Portfolio Pulse from

November 07, 2024 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.